|
**Overview**: Adenovirus Antigen Respiratory Panel**Introduction**: The Adenovirus Antigen Respiratory Panel detects adenovirus in respiratory infections using swab samples. In India, adenovirus causes significant pediatric morbidity, especially in children <5 years, with major outbreaks in West Bengal/Kolkata (2022-2023: >12,000 cases, 150+ child deaths, thousands hospitalized for severe pneumonia/ARI). Prevalence in ARI/SARI: 3-18.57% in multicentric/tertiary studies, higher in 2-5 year olds (recombinant types like HAdV-B 7/3 dominant). Infections present with fever, cough, sore throat, conjunctivitis, progressing to severe pneumonia/ARDS in immunocompromised/young children. High morbidity from underdiagnosis in rural/urban slums, co-infections, limited ICU access. Per virology practices (aligned ICMR/IDSP surveillance), test uses immunofluorescence for parameter analysis over 1-2 days with high sensitivity/specificity, valuable for viral screening amid seasonal peaks (winter/summer). Targets suspected respiratory viral infections in children, addressing accurate pathogen detection for supportive care/antiviral decisions. With elevated morbidity/underdiagnosis in pediatric populations (mortality 23-27% in severe cases), supports public health efforts (vaccination surveillance, outbreak control) for precise identification, management, reduced complications. Swab-based approach ensures reliable detection in India's diverse settings.**Other Names**: Adeno Resp Pnl.**FDA Status**: FDA approved, CLIA certified for virology, compliant with 2025 standards; aligns with ICMR diagnostics.**Historical Milestone**: Introduced 2000s with rapid antigen methods; in India, prominence post-2022-2023 outbreaks highlighting pediatric burden.**Purpose**: Screens for 2 parameters including adenovirus antigen to guide respiratory infection assessment, confirm viral etiology (vs. bacterial/tropical), inform treatment/prevention in high-prevalence pediatric settings.**Test Parameters**: 1. Adenovirus Antigen, 2. Adenovirus Confirmation.**Pretest Condition**: No fasting; report fever, cough, sore throat, respiratory distress, recent outbreaks/exposures.**Specimen**: 1 nasopharyngeal swab in viral transport medium, transported promptly (critical in outbreak scenarios).**Sample Stability at Room Temperature**: 24 hours proper handling to preserve integrity.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, short-term storage preferred immediate testing.**Sample Stability at Frozen**: 1 month at -20 degrees Celsius, storage for retesting.**Medical History**: Details on fever, cough, conjunctivitis, prior ARI, immunosuppression, family/outbreak exposure.**Consent**: Written consent detailing purpose, risks untreated (pneumonia progression/death, high pediatric), benefits early detection, minimal swab discomfort.**Procedural Considerations**: Processing via immunofluorescence by trained personnel, sterile technique, avoid contamination, interpret 1-2 days with controls. Labs controlled, quality assurance, kit storage per specs.**Factors Affecting Result Accuracy**: Delays, improper storage, inadequate sampling, co-infections affect results. Clinical correlation/additional testing recommended.**Clinical Significance**: Positive indicates adenovirus, further investigation/specialist. Negative follow-up if symptoms persist.**Specialist Consultation**: GPs/pediatric infectious disease/pulmonology for management, outbreak coordination.**Additional Supporting Tests**: PCR adenovirus/full respiratory panel confirmation.**Test Limitations**: False negatives low load/cross-reactivity false positives; comprehensive approach with correlation.**References**: ICMR Virology Guidelines 2023, Journal Infectious Diseases India 2024, West Bengal outbreak studies 2023-2025. |
